Effect of Finerenone in IgA Nephropathy

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The aim of this trial is to conduct a randomized, multicenter, placebo-controlled, double-blind clinical trial to determine the safety and efficacy of Finerenone in reducing proteinuria and protecting renal function in patients with IgA nephropathy. The primary endpoint event was the change in urinary albumin/creatinine ratio between the two groups at 12 months of treatment.
Epistemonikos ID: 1af438d4c87dea4477d68a92395d4734a67ce83d
First added on: Sep 01, 2024